Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Ginkgo Bioworks Holdings Inc trades at $8.97 (market cap $593.80M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 67.2× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DNA | |
|---|---|---|
Market Cap | $39.89B | $593.80M |
Sector | Health | Health |
52-Week High | $491.22 | $16.14 |
52-Week Low | $278.09 | $5.48 |
Enterprise Value | $38.15B | $631.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DNA trades at $9.09, down 6.58% on the day, reflecting ongoing investor caution. The technical outlook is bullish based on moving averages, with key support at $9 and resistance at $10. Fundamentally, the company reported a net loss of $312.76M on $170.16M revenue in 2025, with a negative net margin of -201.05%. Recent news highlights include Ginkgo Bioworks' Q1 2026 results and its strategic pivot to autonomous laboratories following the divestiture of its biosecurity business.
The outlook remains challenging due to persistent losses and high cash burn, though the technical setup suggests potential for a near-term bounce. Investment opportunity hinges on successful execution of the new lab strategy driving future profitability. Key risks include continued negative earnings, competitive pressures in biotech, and reliance on the unproven autonomous lab model for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
